Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 16, Issue 3 (May 2014) 16, 331–333; doi: 10.4103/1008-682X.127813

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions

Evan Y Yu1, William K Oh2

1Department of Medicine, Division of Medical
Oncology, University of Washington, Seattle,
WA 98109, USA; 2Division of Hematology and Medical
Oncology, Tisch Cancer Institute, Icahn School of
Medicine at Mount Sinai, New York, NY 10029, USA.

Correspondence: A/Prof. EY Yu (evanyu@u.washington.edu); and Prof. WK Oh (william.oh@mssm.edu)

published online: 08 April 2014

Abstract

The world of prostate cancer has dramatically changed in the last few
years. The original paradigm that metastatic castration‑resistant prostate cancer (mCRPC) is untreatable is clearly wrong.

Full Text | PDF | 中文摘要 |

 
Browse:  1870
 
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved